Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Intervening During Scar Process Could Help Cardiac Patients, Reviewers Say

July 6, 2016 By Virginia Tech

Literal heartbreak, from illness or injury, triggers the body’s natural healing mechanisms. The result of such mending is often a scar. It’s a patch that works, but fibrotic scar tissue replaces healthy heart muscle, a problem that has led scientists across the world to ponder ways to modify the wound-healing process for the benefit of patients. An international team of researchers from the Virginia Tech Carilion Research Institute and the Universities of Bonn and Freiberg in Germany recently published a review paper online in Nature Reviews Drug Discovery that summarizes the potential therapeutic promise of targeting the non-muscle cells in the heart responsible for cardiac scarring. The study is now online and will appear in print in August.

“After disease or injury, the adult mammalian heart repairs by forming a scar, while other classes of vertebrates such as amphibians and fish can regenerate injured cardiac tissue,” says Rob Gourdie, the director of the Virginia Tech Carilion Research Institute’s Center for Heart and Regenerative Medicine and an author of the paper. “Understanding the molecular difference between scarring and regeneration might help us develop treatments for heart disease in humans.”

Annually, more than 600,000 Americans are hospitalized or die from their first heart attack. Of the more than half that survive, 280,000 people will have at least one more coronary event. According the American Heart Association, the annual financial burden of heart disease is $180 billion.

“Heart disease is the leading cause of sickness and death in the developed world,” Gourdie says. “The central problem in heart disease is loss of cardiac muscle and its replacement with fibrotic non-muscle tissue.”

Fibroblasts, the cells responsible for connecting cardiac muscle, make up the fibrotic tissue. Fibroblasts support the walls of the heart in health, but they can thicken and scar in disease, hindering the heart’s ability to contract effectively and pump blood throughout the body, including to the heart muscle itself and the brain.

“Utilizing the natural reparative processes of fibroblasts to modify properties of the forming cardiac scar is quietly emerging as an exciting therapeutic avenue,” says Gourdie, who is also a professor at the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences and a professor of emergency medicine at the Virginia Tech Carilion School of Medicine.

In a related vein, some scientists are attempting to use sophisticated gene therapies to reprogram fibroblasts into different types of adult cells, such as a muscle cells, providing another path to a future way to treat heart disease. Fibroblasts were once thought to simply be the glue holding together cardiac tissue, but now researchers are discovering the complex and active roles these cells play in maintaining the structure and operation of the heart. In a healthy heart, fibroblasts are actually the main type of cell that forms and maintains the connective tissue. The fibroblasts secrete molecules that comprise the extracellular matrix, which acts as scaffolding for the entire heart.

“The concept that fibroblasts link together to form a cardiac sub-system of equal importance to the network of cardiac muscle cells should inform our approach to targeting or even using the connective cells in therapies for heart disease,” Gourdie says. Equally significant, Gourdie noted, is to fully understand the mechanisms underlying communication between cardiac cells. Such knowledge could lead to the development of cell-specific therapeutic delivery systems, among other critical tools to strategically reprogram cell types.

“The topic reviewed in this paper is immensely important for evolving strategies to treat diseases that are routinely viewed as hopeless, from common ailments like advanced heart failure, to rare but deadly ones like muscular dystrophy,” says Eduardo Marbán, the director of Cedars-Sinai Heart Institute. Marbán, who has both a medical degree and a doctorate, was not involved in this review.

A more complete understanding of how cells communicate during and after damage may eventually lead to therapeutic applications for a wide range of diseases and disorders. It’s an admirable aim, and perhaps researchers can start to make a difference for patients now. 

“In the meantime, the more modest goal of modifying scar tissue for patient benefit seems to be a useful tangible objective,” Gourdie says. “Perhaps we can therapeutically nudge or re-engineer the scarring process to improve clinical outcomes for people with heart disease.”

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
An illustration showing the Artedrone Sasha thrombectomy catheter approaching a blood clot.
This microrobot system is designed to float inside a stroke patient for autonomous thrombectomy
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe